GR3030701T3 - Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses. - Google Patents

Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses.

Info

Publication number
GR3030701T3
GR3030701T3 GR990401784T GR990401784T GR3030701T3 GR 3030701 T3 GR3030701 T3 GR 3030701T3 GR 990401784 T GR990401784 T GR 990401784T GR 990401784 T GR990401784 T GR 990401784T GR 3030701 T3 GR3030701 T3 GR 3030701T3
Authority
GR
Greece
Prior art keywords
lewis
antibodies against
monoclonal antibodies
idiotypic
monoclonal antibody
Prior art date
Application number
GR990401784T
Other languages
English (en)
Inventor
Helmut Eckert
Herbert Jaksche
Evelyne Janzek
Hans Loibner
Dieter Scholz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929210930A external-priority patent/GB9210930D0/en
Priority claimed from GB929210944A external-priority patent/GB9210944D0/en
Priority claimed from GB929210929A external-priority patent/GB9210929D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of GR3030701T3 publication Critical patent/GR3030701T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
GR990401784T 1992-05-22 1999-07-07 Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses. GR3030701T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929210930A GB9210930D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB929210944A GB9210944D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB929210929A GB9210929D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
PCT/EP1993/001215 WO1993024647A1 (en) 1992-05-22 1993-05-14 Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses

Publications (1)

Publication Number Publication Date
GR3030701T3 true GR3030701T3 (en) 1999-11-30

Family

ID=27266199

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401784T GR3030701T3 (en) 1992-05-22 1999-07-07 Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses.

Country Status (20)

Country Link
EP (1) EP0644947B1 (el)
JP (3) JPH07507207A (el)
KR (1) KR100279317B1 (el)
AT (1) ATE179214T1 (el)
AU (1) AU678160B2 (el)
CA (1) CA2134751C (el)
CZ (1) CZ286547B6 (el)
DE (1) DE69324584T2 (el)
DK (1) DK0644947T3 (el)
ES (1) ES2133395T3 (el)
FI (1) FI111518B (el)
GR (1) GR3030701T3 (el)
HU (1) HU219055B (el)
NO (1) NO316120B1 (el)
NZ (1) NZ252161A (el)
PL (1) PL175651B1 (el)
RU (1) RU2208642C2 (el)
SG (1) SG50721A1 (el)
SK (1) SK281086B6 (el)
WO (1) WO1993024647A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2162101C1 (ru) * 1999-06-10 2001-01-20 Институт биоорганической химии им. М.М. Шемякина и Ю.А. Овчинникова РАН Тест-система для изучения клеток новообразований (неоплазии)
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
CA2535804A1 (en) * 2003-08-14 2005-03-03 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
JP5985481B2 (ja) * 2010-09-01 2016-09-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗イディオタイプ抗体の迅速な産生
RU2735653C2 (ru) * 2016-08-23 2020-11-05 Тран-Сцелл Биологицс Привате Лимитед Платформа с клетками-предшественниками человека для поиска активных веществ лекарственных препаратов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
JPH03505668A (ja) * 1988-07-06 1991-12-12 ヴェリガン・インコーポレーテッド Ｇｐ４８に対する特異抗体
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
DE69230545T2 (de) * 1991-08-21 2000-07-06 Novartis Ag, Basel Antikörperderivate

Also Published As

Publication number Publication date
FI945485A0 (fi) 1994-11-22
FI111518B (fi) 2003-08-15
EP0644947B1 (en) 1999-04-21
ES2133395T3 (es) 1999-09-16
HUT71311A (en) 1995-11-28
FI945485L (fi) 1994-11-22
WO1993024647A1 (en) 1993-12-09
CA2134751A1 (en) 1993-12-09
NO944443L (no) 1995-01-20
DK0644947T3 (da) 1999-11-01
DE69324584T2 (de) 1999-09-23
EP0644947A1 (en) 1995-03-29
KR950701685A (ko) 1995-04-28
SK139894A3 (en) 1995-07-11
HU219055B (hu) 2001-02-28
JPH11178594A (ja) 1999-07-06
RU2208642C2 (ru) 2003-07-20
CA2134751C (en) 2003-12-16
KR100279317B1 (ko) 2001-01-15
SK281086B6 (sk) 2000-11-07
SG50721A1 (en) 2000-11-21
JP2006143738A (ja) 2006-06-08
RU94046321A (ru) 1997-01-27
NO944443D0 (no) 1994-11-21
DE69324584D1 (de) 1999-05-27
NZ252161A (en) 1996-10-28
CZ286547B6 (cs) 2000-05-17
ATE179214T1 (de) 1999-05-15
CZ285194A3 (en) 1995-05-17
PL175651B1 (pl) 1999-01-29
AU678160B2 (en) 1997-05-22
NO316120B1 (no) 2003-12-15
AU4068893A (en) 1993-12-30
JPH07507207A (ja) 1995-08-10

Similar Documents

Publication Publication Date Title
GR3032944T3 (en) Antibody derivatives.
ZA833686B (en) Human human hybridomas for cervical carcinoma
ATE94205T1 (de) Monoklonale antikoerper gegen melanoma-assoziierte antigene, hybridzellinien, die diese antikoerper produzieren, und ihre verwendung.
NZ568769A (en) Human monoclonal antibodies against CD20
PT865448E (pt) Apoptose induzida pelo anticorpo monoclonal anti-her2
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
ATE171207T1 (de) Monoklonaler antikörper
TW200500377A (en) Method of humanizing immune system molecules
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
AU6927287A (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas
GR3030701T3 (en) Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses.
HU9200293D0 (en) Process for the production of monoclonal antibodies and their fragments
AU3923293A (en) Human monoclonal antibodies and methods for human monoclonal antibody production
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
HUT45092A (en) Process for producing new monoclonal antibodies against ifn-omega and for cleaning and detecting ifn-omega
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
NO922941D0 (no) Medikamenter og fremgangsmaater for behandling av aids og aids-relatert kompleks ved anvendelse av anti-karbohydrat-antistoffer og karbohydrat-antigener
EP0334076A3 (en) Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same
BG50103A1 (en) Hybridome cell line, secretting monoclonal antibody against antigene determinante noc- 2 of malignant melanom in human
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
ATE169332T1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
NO874798D0 (no) Fremgangsmaate for fremstilling av monoklonale antistoffer ved dyrking av hybridom-cellelinjen lym-1.
MX9705445A (es) Anticuerpos monoclonales anti-cd6 y su usos.
BG51638A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant, common for the strains of the virus of haemorrhagic fever with nephritic syndrome " hantaan " , " bulgarian " and " finnish ".